Longidaza®, developed in Russia, received a patent in India. This was reported by the company “Petrovax”. Thus, Longidasa, which already has patents in a number of European countries, is now entering the markets of the BRICS countries.
This drug was developed several years before the start of the pandemic, it is used to treat and prevent diseases accompanied by the formation of adhesions and various types of fibrosis. In 2015, the World Health Organization recognized the originality of the Russian-developed molecule by assigning the international non-proprietary name “bovhyaluronidase azoximer” to the drug.
During the COVID-19 pandemic, when it became clear that the coronavirus affects the lungs, leading to fibrosis, the drug was tested as a remedy for post-COVID complications associated with impaired lung function. Shortness of breath is one of the most common symptoms that can persist for a long time after infection and is a manifestation of inflammatory changes in the lungs in patients who have had COVID. In 2020-2021, within the framework of clinical trials, the drug showed good results in the treatment of patients who underwent covid – they recovered faster after the disease.
Entering the Indian market is another step that continues the expansion of the geographical expansion of the drug. In this country, it is estimated that there are about 130,000 patients diagnosed with idiopathic pulmonary fibrosis who can be shown Longidaza. In general, in the BRICS countries, including, in addition to India, also Brazil, Russia and China, a total need for the drug may be about 2 million people.
In 2021, the drug received a European patent, which is valid in the UK, Germany, France, Switzerland, Ireland and Belgium. Thanks to this, in 2021, sales of the drug in Russia and abroad exceeded 1.7 million packages, while every tenth package is already exported, Petrovax specified.